State Street Corporation has disclosed a significant stake in Twist Bioscience Corp, holding 4.6% of the company’s common stock. This filing, submitted on November 10, 2026, is noteworthy as it highlights the growing interest in the biological products sector.

Twist Bioscience Corp, based in South San Francisco, California, operates within the SIC classification of Biological Products, (No Diagnostic Substances). The company is publicly traded on the Nasdaq under the ticker symbol TWST and is categorized as a large accelerated filer. The recent filing indicates that State Street now beneficially owns 3,017,072 shares of Twist Bioscience, with shared voting power over 2,846,126 shares.

The filing states, "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." This statement emphasizes State Street's intent to maintain a passive investment strategy.

The increase in State Street's stake may impact various stakeholders, including investors, analysts, and competitors in the biological products industry. This move could signal confidence in Twist Bioscience's future growth potential, prompting other investors to reassess their positions in the company and the sector.

Looking ahead, it remains unclear what specific actions may follow this filing. The filing does not say what happens next, leaving stakeholders to speculate on the implications of this investment.